{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T13:42:15Z","timestamp":1790430135847,"version":"4.1.0"},"reference-count":32,"publisher":"MDPI AG","issue":"10","license":[{"start":{"date-parts":[[2021,9,29]],"date-time":"2021-09-29T00:00:00Z","timestamp":1632873600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biomedicines"],"abstract":"<jats:p>Background: Alzheimer\u2019s disease (AD) is the major cause of age-associated cognitive decline, and in the absence of effective therapeutics is progressive and ultimately fatal, creating a dire need for successful prevention and treatment strategies. We recently reported results of a successful proof-of-concept trial, using a personalized, precision medicine protocol, but whether such an approach is readily scalable is unknown. Objective: In the case of AD, there is not a single therapeutic that exerts anything beyond a marginal, unsustained, symptomatic effect. This suggests that the monotherapeutic approach of drug development for AD may not be an optimal one, at least when used alone. Using a novel, comprehensive, and personalized therapeutic system called ReCODE (reversal of cognitive decline), which proved successful in a small, proof-of-concept trial, we sought to determine whether the program could be scaled to improve cognitive and metabolic function in individuals diagnosed with subjective cognitive impairment, mild cognitive impairment, and early-stage AD. Methods: 255 individuals submitted blood samples, took the Montreal Cognitive Assessment (MoCA) test, and answered intake questions. Individuals who enrolled in the ReCODE program had consultations with clinical practitioners, and explanations of the program were provided. Participants had follow-up visits that included education regarding diet, lifestyle choices, medications, supplements, repeat blood sample analysis, and MoCA testing between 2 and 12 months after participating in the ReCODE program. Pre- and post-treatment measures were compared using the non-parametric Wilcoxon signed rank test. Results and Conclusions: By comparing baseline to follow-up testing, we observed that MoCA scores either significantly improved or stabilized in the entire participant pool\u2014results that were not as successful as those in the proof-of-concept trial, but more successful than anti-amyloid therapies\u2014and other risk factors including blood glucose, high-sensitivity C-reactive protein, HOMA-IR, and vitamin D significantly improved in the participant pool. Our findings provide evidence that a multi-factorial, comprehensive, and personalized therapeutic program designed to mitigate AD risk factors can improve risk factor scores and stabilize or reverse the decline in cognitive function. Since superior results were obtained in the proof-of-concept trial, which was conducted by a small group of highly trained and experienced physicians, it is possible that results from the use of this personalized approach would be enhanced by further training and experience of the practicing physicians. Nonetheless, the current results provide further support indicating the potential of such an approach for the prevention and reversal of cognitive decline.<\/jats:p>","DOI":"10.3390\/biomedicines9101348","type":"journal-article","created":{"date-parts":[[2021,9,29]],"date-time":"2021-09-29T08:27:44Z","timestamp":1632904064000},"page":"1348","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["ReCODE: A Personalized, Targeted, Multi-Factorial Therapeutic Program for Reversal of Cognitive Decline"],"prefix":"10.3390","volume":"9","author":[{"given":"Rammohan V","family":"Rao","sequence":"first","affiliation":[{"name":"Apollo Health, Burlingame, CA 94011, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharanya","family":"Kumar","sequence":"additional","affiliation":[{"name":"Voluntary Data Scientist, Chennai 600083, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Gregory","sequence":"additional","affiliation":[{"name":"Apollo Health, Burlingame, CA 94011, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Coward","sequence":"additional","affiliation":[{"name":"Apollo Health, Burlingame, CA 94011, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sho","family":"Okada","sequence":"additional","affiliation":[{"name":"Apollo Health, Burlingame, CA 94011, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Lipa","sequence":"additional","affiliation":[{"name":"Apollo Health, Burlingame, CA 94011, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lance","family":"Kelly","sequence":"additional","affiliation":[{"name":"Apollo Health, Burlingame, CA 94011, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dale E","family":"Bredesen","sequence":"additional","affiliation":[{"name":"Apollo Health, Burlingame, CA 94011, USA"},{"name":"Department of Molecular and Medical Pharmacology, University of California, Los Angeles, CA 90024, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,9,29]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"(2021). 2021 Alzheimer\u2019s disease facts and figures. J. Alzheimer\u2019s Assoc., 17, 327\u2013406.","DOI":"10.1002\/alz.12328"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"323","DOI":"10.3233\/JAD-190426","article-title":"Tip of the Iceberg: Assessing the Global Socioeconomic Costs of Alzheimer\u2019s Disease and Related Dementias and Strategic Implications for Stakeholders","volume":"70","author":"Wiley","year":"2019","journal-title":"J. Alzheimer\u2019s Dis."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1212\/WNL.0000000000000240","article-title":"Contribution of Alzheimer disease to mortality in the United States","volume":"82","author":"James","year":"2014","journal-title":"Neurology"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"86","DOI":"10.3934\/Neuroscience.2021005","article-title":"The biological pathways of Alzheimer disease: A review","volume":"8","author":"Calabro","year":"2021","journal-title":"AIMS Neurosci."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1089\/ars.2019.7763","article-title":"Central and Peripheral Metabolic Defects Contribute to the Pathogenesis of Alzheimer\u2019s Disease: Targeting Mitochondria for Diagnosis and Prevention","volume":"32","author":"Peng","year":"2020","journal-title":"Antioxid. Redox Signal."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.tem.2010.05.005","article-title":"Alzheimer\u2019s disease: Brain expression of a metabolic disorder?","volume":"21","author":"Merlo","year":"2010","journal-title":"Trends Endocrinol. Metab."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/j.cmet.2015.08.016","article-title":"Metabolic and Non-Cognitive Manifestations of Alzheimer\u2019s Disease: The Hypothalamus as Both Culprit and Target of Pathology","volume":"22","author":"Ishii","year":"2015","journal-title":"Cell Metab."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"707","DOI":"10.18632\/aging.100690","article-title":"Reversal of cognitive decline: A novel therapeutic program","volume":"6","author":"Bredesen","year":"2014","journal-title":"Aging (Albany NY)"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1523\/JNEUROSCI.3562-15.2016","article-title":"Direct Transcriptional Effects of Apolipoprotein E","volume":"36","author":"Theendakara","year":"2016","journal-title":"J. Neurosci."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"8501693","DOI":"10.1155\/2016\/8501693","article-title":"Current Research Therapeutic Strategies for Alzheimer\u2019s Disease Treatment","volume":"2016","author":"Folch","year":"2016","journal-title":"Neural Plast."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1016\/S0140-6736(15)60461-5","article-title":"A 2 year multidomain intervention of diet, exercise, cognitive training, and vascular risk monitoring versus control to prevent cognitive decline in at-risk elderly people (FINGER): A randomised controlled trial","volume":"385","author":"Ngandu","year":"2015","journal-title":"Lancet"},{"key":"ref_12","first-page":"223","article-title":"A Comprehensive, Multi-Modal Strategy to Mitigate Alzheimer\u2019s Disease Risk Factors Improves Aspects of Metabolism and Offsets Cognitive Decline in Individuals with Cognitive Impairment","volume":"4","author":"Schechter","year":"2020","journal-title":"J. Alzheimer\u2019s Dis. Rep."},{"key":"ref_13","first-page":"1","article-title":"Reversal of Cognitive Decline: 100 Patients","volume":"8","author":"Bredesen","year":"2018","journal-title":"J. Alzheimer\u2019s Dis. Parkinsonism"},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Toups, K., Hathaway, A., Gordon, D., Chung, H., Raji, C., Boyd, A., Hill, B.D., Hausman-Cohen, S., Attarha, M., and Chwa, W.J. (2021). Precision Medicine Approach to Alzheimer\u2019s Disease: Successful Proof-of-Concept Trial. medRxiv.","DOI":"10.1101\/2021.05.10.21256982"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.18632\/aging.100981","article-title":"Reversal of cognitive decline in Alzheimer\u2019s disease","volume":"8","author":"Bredesen","year":"2016","journal-title":"Aging (Albany NY)"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"18303","DOI":"10.1073\/pnas.1314145110","article-title":"Neuroprotective Sirtuin ratio reversed by ApoE4","volume":"110","author":"Theendakara","year":"2013","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Theendakara, V., Peters-Libeu, C.A., Bredesen, D.E., and Rao, R.V. (2017). Transcriptional Effects of ApoE4: Relevance to Alzheimer\u2019s Disease. Mol. Neurobiol.","DOI":"10.1007\/s12035-017-0757-2"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1002\/ana.10265","article-title":"Early inflammation and dementia: A 25-year follow-up of the Honolulu-Asia Aging Study","volume":"52","author":"Schmidt","year":"2002","journal-title":"Ann. Neurol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1001\/archneurol.2009.308","article-title":"Association of C-reactive protein with cognitive impairment","volume":"67","author":"Noble","year":"2010","journal-title":"Arch. Neurol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.3389\/fimmu.2018.01302","article-title":"The Clinical Significance and Potential Role of C-Reactive Protein in Chronic Inflammatory and Neurodegenerative Diseases","volume":"9","author":"Luan","year":"2018","journal-title":"Front. Immunol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"595","DOI":"10.18632\/aging.100801","article-title":"Metabolic profiling distinguishes three subtypes of Alzheimer\u2019s disease","volume":"7","author":"Bredesen","year":"2015","journal-title":"Aging (Albany NY)"},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Chai, B., Gao, F., Wu, R., Dong, T., Gu, C., Lin, Q., and Zhang, Y. (2019). Vitamin D deficiency as a risk factor for dementia and Alzheimer\u2019s disease: An updated meta-analysis. BMC Neurol., 19.","DOI":"10.1186\/s12883-019-1500-6"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1212\/WNL.0000000000000755","article-title":"Vitamin D and the risk of dementia and Alzheimer disease","volume":"83","author":"Littlejohns","year":"2014","journal-title":"Neurology"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"830","DOI":"10.3389\/fnins.2018.00830","article-title":"Insulin Resistance in Alzheimer\u2019s Disease","volume":"12","author":"Ferreira","year":"2018","journal-title":"Front. Neurosci."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"475","DOI":"10.5483\/BMBRep.2009.42.8.475","article-title":"Insulin resistance and Alzheimer\u2019s disease","volume":"42","year":"2009","journal-title":"BMB Rep."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Nguyen, T.T., Ta, Q.T.H., Nguyen, T.K.O., Nguyen, T.T.D., and Giau, V.V. (2020). Type 3 Diabetes and Its Role Implications in Alzheimer\u2019s Disease. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21093165"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.3233\/JAD-160110","article-title":"Insulin Resistance is Associated with Increased Levels of Cerebrospinal Fluid Biomarkers of Alzheimer\u2019s Disease and Reduced Memory Function in At-Risk Healthy Middle-Aged Adults","volume":"52","author":"Hoscheidt","year":"2016","journal-title":"J. Alzheimers Dis."},{"key":"ref_28","unstructured":"Morris, J.C. (2005). Mild cognitive impairment and preclinical Alzheimer\u2019s disease. Geriatrics, 9\u201314."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/j.ncl.2007.03.008","article-title":"Alzheimer\u2019s disease and mild cognitive impairment","volume":"25","author":"Kelley","year":"2007","journal-title":"Neurol. Clin."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"304","DOI":"10.18632\/aging.100896","article-title":"Inhalational Alzheimer\u2019s disease: An unrecognized-and treatable-epidemic","volume":"8","author":"Bredesen","year":"2016","journal-title":"Aging (Albany NY)"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1177\/070674370705200508","article-title":"The Montreal Cognitive Assessment: Validity and utility in a memory clinic setting","volume":"52","author":"Smith","year":"2007","journal-title":"Can. J. Psychiatry"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1177\/1073191116654217","article-title":"Changes in Montreal Cognitive Assessment Scores Over Time","volume":"24","author":"Krishnan","year":"2017","journal-title":"Assessment"}],"container-title":["Biomedicines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2227-9059\/9\/10\/1348\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T07:06:59Z","timestamp":1760166419000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2227-9059\/9\/10\/1348"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,29]]},"references-count":32,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2021,10]]}},"alternative-id":["biomedicines9101348"],"URL":"https:\/\/doi.org\/10.3390\/biomedicines9101348","relation":{},"ISSN":["2227-9059"],"issn-type":[{"value":"2227-9059","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,29]]}}}